The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gorbunov A.S.

Cardiology Research Institute, Tomsk National Research Medical Center

Sidorova M.V.

Chazov National Medical Research Center of Cardiology

Palkeeva M.E.

Chazov National Medical Research Center of Cardiology

Molokoedov A.S.

Chazov National Medical Research Center of Cardiology

Pisarenko O.I.

Chazov National Medical Research Center of Cardiology

Exogenous GalR2 receptor agonist reduces reperfusion injury in isolated rat heart

Authors:

Gorbunov A.S., Sidorova M.V., Palkeeva M.E., Molokoedov A.S., Pisarenko O.I.

More about the authors

Journal: Russian Cardiology Bulletin. 2024;19(3): 37‑42

DOI: 10.17116/Cardiobulletin20241903137

Read: 950 times

Download PDF (RU)
Contact the author
Table of contents

EXOGENOUS GALR2 RECEPTOR AGONIST REDUCES REPERFUSION INJURY IN ISOLATED RAT HEART
EXOGENOUS GALR2 RECEPTOR AGONIST REDUCES REPERFUSION INJURY IN ISOLATED RAT HEART

To cite this article:

Gorbunov AS, Sidorova MV, Palkeeva ME, Molokoedov AS, Pisarenko OI. Exogenous GalR2 receptor agonist reduces reperfusion injury in isolated rat heart. Russian Cardiology Bulletin. 2024;19(3):37‑42. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20241903137

 
ЭндоКард
Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Stroke: current state of the problem. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):7-18
Prevention of repe­rfusion injury in cardiac surgery. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(4):471-477
Analysis of the causes of late diagnosis of vascular myelopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):117-123
Abstract:

OBJECTIVE

To study the effect of exogenous GalR2 receptor agonist (peptide H-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-βAla-His-OH) (G) on reperfusion injury after total ischemia in isolated rat heart model.

MATERIAL AND METHODS

Isolated hearts of Wistar rats perfused with Krebs-Henseleit solution (KHS) according to the Langendorff method were subjected to total normothermic ischemia and reperfusion. In the group G, rat heart was reperfused by KHS containing peptide 5 μg/ml within 10 min. No peptide was infused for further 20min reperfusion. Reperfusion by KHS was carried out in the control group. We estimated recovery of cardiac function and necrotic damage to cardiomyocytes.

RESULTS

Recovery of left ventricle pressure, heart rate, maximum rate of left ventricular contraction and relaxation (+dP/dt and — dP/dt, respectively) was more effective under the influence of G compared to the control group (p<0.05—0.01). End-diastolic pressure significantly decreased in the same group. Total release of creatine phosphokinase into perfusate was significantly less in the group G compared to the control group.

CONCLUSION

These results indicate possible direct effect of G on myocardium. Lower cardiac reperfusion injury is associated with kinase cascades following activation of GalR2 receptor by G agonist.

Keywords:

isolated perfused rat heart
ischemia
reperfusion
GalR2 receptor agonist
intracellular signaling

Authors:

Gorbunov A.S.

Cardiology Research Institute, Tomsk National Research Medical Center

Sidorova M.V.

Chazov National Medical Research Center of Cardiology

Palkeeva M.E.

Chazov National Medical Research Center of Cardiology

Molokoedov A.S.

Chazov National Medical Research Center of Cardiology

Pisarenko O.I.

Chazov National Medical Research Center of Cardiology

Received:

31.01.2024

Accepted:

17.04.2024

Close metadata

References:

  1. Branchek TA, Smith KE, Gerald C, Walker MW. Galanin receptor subtypes. Trends in Pharmacological Sciences. 2000;21:109-117.  https://doi.org/10.1016/s0165-6147(00)01446-2
  2. Abbott S, Pilowsky P. Galanin microinjection into rostral ventrolateral medulla of the rat is hypotensive and attenuates sympathetic chemoreflex. American journal of physiology. Regulatory, integrative and comparative physiology. 2009;296(4):R1019-R1026. https://doi.org/10.1152/ajpregu.90885.2008
  3. Alston EN, Parrish DC, Hasan W, Tharp K, Pahlmeyer L, Habecker BA. Cardiac ischemia–reperfusion regulates sympathetic neuropeptide expression through gp130-dependent and independent mechanisms. Neuropeptides. 2011;45(1):33-42.  https://doi.org/10.1016/j.npep.2010.10.002
  4. Webling KEB, Runesson J, Bartfai T, Langel Ü. Galanin receptors and ligands. Frontiers in Endocrinology. 2012;3:146. 
  5. Boal F, Cinato M, Timotin A, Münzberg H, Qualls-Creekmore E, Kramar S, Loi H, Roncalli J, Keita S, Tronchere H, Kunduzova O. Galanin Regulates Myocardial Mitochondrial ROS Homeostasis and Hypertrophic Remodeling Through GalR2. Frontiers in Pharmacology. 2022;13:869179. https://doi.org/10.3389/fphar.2022.869179
  6. Timotin A, Pisarenko O, Sidorova M, Studneva I, Shulzhenko V, Palkeeva M, Serebryakova L, Molokoedov A, Veselova O, Cinato M, Boal F, Tronchere H, Kunduzova O. Myocardial protection from ischemia/reperfusion injury by exogenous galanin fragment. Oncotarget. 2017;8:21241-21252. https://doi.org/10.18632/oncotarget.15071
  7. Pisarenko O, Timotin A, Sidorova M, Studneva I, Shulzhenko V, Palkeeva M, Serebryakova L, Molokoedov A, Veselova O, Cinato M, Boal F, Tronchere H, Kunduzova O. Cardioprotective properties of N-terminal galanin fragment (2-15) in experimental ischemia/reperfusion injury. Oncotarget. 2017;8:101659-101671.
  8. Palkeeva M, Studneva I, Molokoedov A, Serebryakova L, Veselova O, Ovchinnikov M, Sidorova M, Pisarenko O. Galanin/GalR1-3 system: a promising therapeutic target for myocardial ischemia/reperfusion injury. Biomedicine & Pharmacotherapy. 2019;109:1556-1562.
  9. Studneva I, Palkeeva M, Veselova O, Molokoedov A, Ovchinnikov M, Sidorova M, Pisarenko O. Protective Effects of a Novel Agonist of Galanin Receptors Against Doxorubicin-Induced Cardiotoxicity in Rats. Cardiovascular Toxicology. 2019;19:136-146.  https://doi.org/10.1007/s12012-018-9483-x
  10. Studneva IM, Veselova OM, Bakhtin AA, Konovalova GG, Lankin VZ, Pisarenko OI. Mechanisms of cardiac protection by a synthetic galanin receptor agonist during damage by chronic administration of doxorubicin. Acta Naturae. 2020;1(12):89-98. (In Russ.). https://doi.org/10.32607/actanaturae.10945
  11. Runesson J, Saar I, Lundström L, Jarv J, Langel U. A novel GalR2-specific peptide agonist. Neuropeptides. 2009;43:187-192.  https://doi.org/10.1016/j.npep.2009.04.004
  12. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discovery Today. 2010;15(1/2):40-56.  https://doi.org/10.1016/j.drudis.2009.10.009
  13. Fmoc Solid Phase Peptide Synthesis. Practical Approach. WC Chan, PD White, eds. N.Y.: Oxford University Press; 2004.
  14. Shulzhenko VS, Serebryakova LI, Studneva IM, Pelogeykina YA, Veselova OM, Molokoedov AS, Ovchinnikov MV, Palkeeva ME, Sidorova MV, Pisarenko OI. Ability of n-terminal fragment of neuropeptide galanin to attenuate ischemia and reperfusion injury of rat heart. Russian Cardiology Bulletin. 2016;11(3):12-21. (In Russ.).
  15. Liu HX, Brumovsky P, Schmidt R, Brown W, Payza K, Hodzic L, Pou C, Godbout C, Hökfelt T. Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: Selective actions via GalR1 and GalR2 receptors. Proceedings of the National Academy of Sciences of the USA. 2001;98:9960-9964. https://doi.org/10.1073/pnas.161293598
  16. Webling K, Runesson J, Lang A, Saar I, Kofler B, Langel U. Ala5-galanin (2-11) is a GAL2R specific galanin analogue. Neuropeptides. 2016;60:75-82.  https://doi.org/10.1016/j.npep.2016.08.008
  17. Serebryakova L, Veselova O, Studneva I, Dobrokhotov I, Palkeeva M, Avdeev D, Molokoedov A, Ovchinnikov M, Sidorova M, Pisarenko O. Exogenous GalR2-specific peptide agonist as a tool for treating myocardial ischemia/reperfusion injury. Fundamental and Clinical Pharmacology. 2023;37(6):1109-1118. https://doi.org/10.1111/fcp.12925
  18. Waters SM, Krause JE. Distribution of galanin-1, -2 and- 3 receptor messenger RNAs in central and peripheral rat tissues. Neuroscience. 2000;95(1):265-271.  https://doi.org/10.1016/s0306-4522(99)00407-8
  19. Pisarenko OI, Studneva IM, Veselova OM. Modified N-terminal fragments of galanin: Cardioprotective properties and mechanisms of action. Biochimia. 2021;86(10):1502-1512. (In Russ.). https://doi.org/10.31857/S0320972521100079
  20. Fang P, Shib M, Guo L, He B, Wang Q, Yu M, Bo P, Zhang Z. Effect of endogenous galanin on glucose transporter 4 expression in cardiac muscle of type 2 diabetic rats. Peptides. 2014;62:159-163.  https://doi.org/10.1016/j.peptides.2014.10.001
  21. Doehner W, Gathercole D, Cicoira M, Krack A, Coats AJS, Camici PG, Anker SD. Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body composition. International Journal of Cardiology. 2010;138:19-24.  https://doi.org/10.1016/j.ijcard.2008.07.004
  22. Lang R, Gundlach AL, Holmes FE, Hobson SA, Wynick D, Hökfelt T, Kofler B. Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacological Reviews. 2015;67:118-175.  https://doi.org/10.1124/pr.112.006536
  23. Krijnen PA, Nijmeijer R, Meijer CJ, Visser CA, Hack CE, Niessen HW. Apoptosis in myocardial ischaemia and infarction. Journal of Clinical Pathology. 2002;55:801-811.  https://doi.org/10.1136/jcp.55.11.801
  24. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. Journal of Clinical Investigation. 2013;123:92-100.  https://doi.org/10.1172/JCI62874
  25. Jay MA, Ren J. Peroxisome proliferator- activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Current Diabetes Reviews. 2007;3:33-39.  https://doi.org/10.2174/157339907779802067
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.